Beam Therapeutics Inc. (BEAM)

Updated Data from 31 Adult and Adolescent SCD Patients  Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to...

Capital Fund Management S.A. acquired a new stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Com...

Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,...

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?...

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects....

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago....

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early ...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...

Beam Therapeutics (BEAM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could ...